ProMIS Neurosciences Reports $11.6M Net Loss in Q3 2025 Amid Rising Expenses

ProMIS Neurosciences Inc. reported significant financial challenges in its latest 10-Q filing for the third quarter of 2025, with a net loss of $11.6 million for the three months ending September 30, 2025, compared to a net income of $9.3 million in the same period last year. For the nine months ended September 30, 2025, the company recorded a net loss of $29.0 million, a stark contrast to a net income of $3.0 million for the same period in 2024. The substantial losses are attributed to increased operating expenses, particularly in research and development, which surged to $24.0 million for the nine months, up from $6.3 million in the prior year.

The company's total operating expenses for the third quarter reached $11.8 million, a 165% increase from $4.4 million in the same quarter of 2024. This increase was primarily driven by heightened research and development costs associated with the ongoing Phase 1b clinical trial of PMN310, its lead product candidate targeting Alzheimer’s disease. The company has also seen a significant rise in general and administrative expenses, which totaled $5.4 million for the nine months ended September 30, 2025, compared to $4.5 million in the previous year.

In terms of operational developments, ProMIS has made strides in its clinical programs, particularly with PMN310, which received Fast Track Designation from the FDA in July 2025. The company is currently conducting a Phase 1b trial, with complete enrollment expected by the end of 2025. Additionally, ProMIS has expanded its shareholder base, increasing its common shares outstanding from 32.7 million at the end of 2024 to 53.8 million as of September 30, 2025, through various financing activities, including discounted warrant exercises and private placements, which raised approximately $21.6 million in gross proceeds.

Despite these efforts, ProMIS faces liquidity challenges, with cash reserves of $15.4 million as of September 30, 2025, which management believes may not be sufficient to fund operations for the next 12 months. The company has indicated that it will need to secure additional funding through public and private financings, collaborations, or strategic alliances to continue its research and development activities. The ongoing financial losses and the need for substantial additional funding raise significant doubt about the company's ability to continue as a going concern.

Looking ahead, ProMIS anticipates continued net losses as it advances its product candidates through clinical trials. The company is actively pursuing additional financing options to support its growth strategy, which includes expanding its research and development efforts and potentially in-licensing or acquiring new product candidates. However, the current economic environment, characterized by rising interest rates and market volatility, may pose challenges in securing the necessary funding on favorable terms.